The first cohort of three patients under the amended protocol has completed the six-week safety evaluation. One patient had a dose-limiting toxicity (DLT), so three more patients will be enrolled at the same dose before the recommended phase II dose (RP2D) can be set, meaning the efficacy part of the study moves somewhat further out.
LÄS MER
